Cranswick plc (LON:CWK – Get Free Report) insider Mark Bottomley sold 430 shares of the firm’s stock in a transaction that occurred on Tuesday, September 24th. The stock was sold at an average price of GBX 4,658 ($62.37), for a total transaction of £20,029.40 ($26,820.30).
Mark Bottomley also recently made the following trade(s):
- On Tuesday, August 6th, Mark Bottomley sold 8,197 shares of Cranswick stock. The shares were sold at an average price of GBX 4,519 ($60.51), for a total transaction of £370,422.43 ($496,012.90).
Cranswick Stock Performance
Shares of LON CWK traded down GBX 25 ($0.33) during midday trading on Tuesday, reaching GBX 4,660 ($62.40). 157,923 shares of the company were exchanged, compared to its average volume of 137,938. The stock has a market cap of £2.50 billion, a P/E ratio of 2,228.57, a PEG ratio of 2.62 and a beta of 0.44. Cranswick plc has a 1 year low of GBX 3,392 ($45.42) and a 1 year high of GBX 4,835 ($64.74). The stock has a fifty day simple moving average of GBX 4,564.44 and a 200 day simple moving average of GBX 4,387.51. The company has a current ratio of 1.66, a quick ratio of 1.02 and a debt-to-equity ratio of 13.88.
Analysts Set New Price Targets
Check Out Our Latest Research Report on CWK
About Cranswick
Cranswick plc manufactures and supplies food products to grocery retailers, food service sector, and other food producers in the United Kingdom, Continental Europe, and internationally. The company offers fresh pork, gourmet bacon and gammon, fresh and coated chicken, ready to eat chicken, charcuterie, houmous and dips, and olives and antipasti, gourmet sausages, cooked meats, and gourmet pastries, as well as provides food services.
Recommended Stories
- Five stocks we like better than Cranswick
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Industrial Products Stocks Investing
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Cranswick Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cranswick and related companies with MarketBeat.com's FREE daily email newsletter.